Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile

Curr Drug Targets. 2019;20(13):1327-1338. doi: 10.2174/1389450120666190320110809.

Abstract

Crohn's disease (CD) is an immune-mediated condition characterized by the transmural inflammation of the gut tissue, associated with progressive bowel damage often leading to surgical intervention. As operative resection of the damaged segment is not curative, a majority of patients undergoing intestinal resections for complicated CD present disease recurrence within 3 years after the intervention. Postoperative recurrence can be defined as endoscopic, clinical, radiological or surgical. Endoscopic recurrence rates within 1 year exceed 60% and the severity, according to the Rutgeerts' score, is associated with worse prognosis and can predict clinical recurrence (in up to 1/3 of the patients). Most importantly, about 50% of patients will undergo a reoperation after 10 years of their first intestinal resection. Therefore, the prevention of postoperative recurrence in CD remains a challenge in clinical practice and should be properly managed. We aim to summarize the most recent data on the definition, risk factors, assessment and treatment of postoperative CD recurrence.

Keywords: Crohn's disease; immune-mediated; postoperative recurrence; prevention; surgery treatment; transmural inflammation..

Publication types

  • Systematic Review

MeSH terms

  • Ciprofloxacin / therapeutic use
  • Colitis, Ulcerative / surgery*
  • Humans
  • Metronidazole / therapeutic use
  • Patient-Centered Care
  • Pouchitis / prevention & control*
  • Practice Guidelines as Topic
  • Proctocolectomy, Restorative / adverse effects*
  • Randomized Controlled Trials as Topic
  • Rifaximin / therapeutic use

Substances

  • Metronidazole
  • Ciprofloxacin
  • Rifaximin